Tegmine Therapeutics is a private, seed-stage biotech that develops antibody-based therapeutics targeting proteins and their disease-related glycan modifications. This class of therapeutics is more selective for the tumor, sparing normal healthy tissues, and will be formatted as ADCs, CAR-T’s, radiotherapies, or bi-specific antibodies. Tegmine is headquartered in the San Francisco Bay Area. Learn more at tegminetx.com and follow for updates on LinkedIn.